Skip to main content
SpringerLink
Log in

Novel Drugs and Current Therapeutic Approaches in the Treatment of Heart Failure

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Treatment of heart failure attempts to reduce symptoms, increase functional capacity and prolong survival. Optimal therapy usually requires a combination of several drugs. At present, ACE inhibitors are the drugs of first choice, but must be combined with diuretics in symptomatic patients. Digitalis glycosides are still an important supplement to diuretics and ACE inhibitors. Specific angiotensin receptor antagonists such as losartan have an effect comparable with that of ACE inhibitors and may possess certain advantages because of their direct effect at the receptor level.

Extensive research has been conducted in the treatment of heart failure. Newer direct acting vasodilators such as flosequinan and epoprostenol have demonstrated improved exercise tolerance but have an adverse effect on mortality. Positive inotropic agents consisting of a heterogeneous group of drugs have been evaluated. Although novel agents such as xamoterol, milrinone, pimobendan and vesnarinone have demonstrated improved haemodynamics and improved symptoms, they are not advisable at present due to increased mortality related to treatment or a high incidence of adverse events.

β-Blockers, used judiciously, may improve functional capacity as well as mortality and may be an important supplement to current conventional treatment. The new generation of β-blockers with vasodilating properties such as Carvedilol and bucindolol appear promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302

    Article  Google Scholar 

  2. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–28

    Google Scholar 

  3. Pfeffer M, Braunwald E, Moyé LA, et al., on behalf of the SAVE investigators. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77

    Article  PubMed  CAS  Google Scholar 

  4. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrite in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10

    Article  PubMed  CAS  Google Scholar 

  5. SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asympomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91

    Article  Google Scholar 

  6. Richardson A, Bayliss J, Sciven AJ, et al. Double blind comparison of Captopril alone against frusemide plus amiloride in mild heart failure. Lancet 1987; 2: 709–11

    Article  PubMed  CAS  Google Scholar 

  7. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468–75

    Article  PubMed  CAS  Google Scholar 

  8. Cleland J, Dargie H, Ball S, et al. Effects of enalapril in heart failure: a double-blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985; 54: 305–12

    Article  PubMed  CAS  Google Scholar 

  9. Creager MA, Faxon DP, Weiner DA, et al. Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with Captopril. Br Heart J 1985; 53: 431–5

    Article  PubMed  CAS  Google Scholar 

  10. Drexler H, Banhardt U, Meinertz T, et al. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. Circulation 1989; 79: 491–502

    Article  PubMed  CAS  Google Scholar 

  11. Kramer B, Topic N, Massie B. Acute and long-term effects of Captopril in exercise cardiac performance and exercise capacity in congestive heart failure. Br J Clin Pharmacol 1982; 14: 143–51

    Article  Google Scholar 

  12. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–35

    Article  Google Scholar 

  13. Kirlin PC, Grekin R, Das S, et al. Neurohumoral activation during exercise in congestive heart failure. Am J Med 1986; 81: 623–9

    Article  PubMed  CAS  Google Scholar 

  14. Wilson JR, Ferraro N. Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure. Am J Cardiol 1985; 6: 556–63

    Article  CAS  Google Scholar 

  15. Mancini DM, Davis L, Wexler JP, et al. Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term Captopril therapy in heart failure. J Am Coll Cardiol 1987; 10; 845–50

    Article  PubMed  CAS  Google Scholar 

  16. Corbalan R, Jalil J, Chamorro G, et al. Effects of Captopril versus milrinone therapy in modulating the adrenergic nervous system response to exercise in congestive heart failure. Am J Cardiol 1990; 65: 644–9

    Article  PubMed  CAS  Google Scholar 

  17. Bonarjee VVS, Carstensen S, Caidahl K, et al. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. Am J Cardiol 1993; 72: 1004–9

    Article  PubMed  CAS  Google Scholar 

  18. Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991; 337: 872–6

    Article  PubMed  CAS  Google Scholar 

  19. Lamas G, Vaughan D, Parisi A, et al. Effects of left ventricular shape and Captopril therapy on exercise capacity after anterior wall acute myocardial infarction. Am J Cardiol 1989; 63: 1167–73

    Article  PubMed  CAS  Google Scholar 

  20. Dickstein K, Aarsland T. Effect on exercise performance of enalapril therapy initiated early after myocardial infarction. J Am Coll Cardiol 1993; 22: 975–83

    Article  PubMed  CAS  Google Scholar 

  21. Smith TS, Braunwald E, Kelly RA. The management of heart failure. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 4th ed. Philadelphia: WB Saunders Co., 1992: 470–9

    Google Scholar 

  22. Coewley AJ, Stainer K, Wynne RD, et al. Symtomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and Captopril in moderate heart failure. Lancet 1986; 2: 770–2

    Article  Google Scholar 

  23. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886–94

    PubMed  CAS  Google Scholar 

  24. Kiyingi A, Field MJ, Paussel CC, et al. Metolazone and treatment of severe refractory congestive heart failure. Lancet 1990; 335: 29–31

    Article  PubMed  CAS  Google Scholar 

  25. Weber KT, Brilla CC. Pathologic hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849–65

    Article  PubMed  CAS  Google Scholar 

  26. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long term angiotensin II suppression. J Endocrinol 1981; 91: 457–65

    Article  PubMed  CAS  Google Scholar 

  27. van Vliet AA, Donker AJM, Nauta JJP, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin converting enzyme inhibitor. Am J Cardiol 1993; 71: 21A–8A

    Article  PubMed  Google Scholar 

  28. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980; 303: 1443–8

    Article  PubMed  CAS  Google Scholar 

  29. Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Circulation 1989; 80: 65–77

    Article  PubMed  CAS  Google Scholar 

  30. Gheorghiade M, Hall V, Lakier JB, et al. Comparative hemodynamic and neurohormonal effects of intravenous Captopril and digoin and their combination in patients with severe heart failure. J Am Coll Cardiol 1989; 13: 134–42

    Article  PubMed  CAS  Google Scholar 

  31. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors: RADIANCE study. N Engl J Med 1993; 329: 1–7

    Article  PubMed  CAS  Google Scholar 

  32. Uretsky BF, Young JB, Shahidi FD, et al., on behalf of the PROVED investigative 3group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955–62

    Article  PubMed  CAS  Google Scholar 

  33. Neuberg GW, Kukin ML, Penn J, et al. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol 1991; 67: 63–6

    Article  PubMed  CAS  Google Scholar 

  34. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens 1987; 9: 243–59

    Article  CAS  Google Scholar 

  35. Streeten DHP, Andersen GH. Angiotensin receptor blocking drugs. In: Doyle AE, editor. Handbook of hypertension. Vol. 5: clinical pharmacology of antihypertensive drugs. New York/Amsterdam: Elsevier Science Publishing Co. Inc., 1984: 246–71

    Google Scholar 

  36. Fogari R, Zoppi A, Tettamanti F, et al. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 1992; 19: 670–3

    PubMed  CAS  Google Scholar 

  37. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883–90

    Article  PubMed  CAS  Google Scholar 

  38. Grinstead WC, Young JB. The myocardial renin-angiotensin system: existence, importance, and clinical implications. Am Heart J 1992; 123: 1039–45

    Article  PubMed  CAS  Google Scholar 

  39. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of response to exogenous angiotensin I and II. Circulation 1991; 83: 1333–42

    Article  PubMed  CAS  Google Scholar 

  40. Gottleib S, Dickstein K, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602–9

    Article  Google Scholar 

  41. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691–7

    Article  PubMed  CAS  Google Scholar 

  42. Dickstein K, Chang PD, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438–45

    Article  PubMed  CAS  Google Scholar 

  43. Simon S, Black H, Moser M, et al. Cough and ACE inhibitors. Arch Intern Med 1992; 152: 1698–700

    Article  PubMed  CAS  Google Scholar 

  44. Lindgren B, Anderson R. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough: a research review. Med Toxicol Adverse Drug Exper 1989; 4: 369–80

    CAS  Google Scholar 

  45. Kiowski W, Beerman J, Rickenbacher P, et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure: assessment by acute renin and converting enzyme inhibition. Circulation 1994; 90: 2748–56

    Article  PubMed  CAS  Google Scholar 

  46. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545–50

    Article  PubMed  CAS  Google Scholar 

  47. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20: 1549–55

    Article  PubMed  CAS  Google Scholar 

  48. Baur LHB, Schipperheyn JJ, van der Laarse A, et al. Combining salicylate and enalapril in pateints with coronary artery disease and heart failure. Br Heart J 1995; 73: 227–36

    Article  PubMed  CAS  Google Scholar 

  49. Dzau VJ. Molecular biology and heterogeneity of angiotensin II receptors. J Hypertens 1994; 12: S1–5

    CAS  Google Scholar 

  50. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality and chronic congestive heart failure: results of the Veterans Administration cooperative study. N Engl J Med 1986; 314: 1547–52

    Article  PubMed  CAS  Google Scholar 

  51. Fonarrow GC, Chemlimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilation with hydralazine vs angiotensin-converting enzyme inhibition with Captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992; 19: 842–50

    Article  Google Scholar 

  52. Hirsch AT, Pinto YM, Schunkert H, et al. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990; 66: 22D–32D

    Article  PubMed  CAS  Google Scholar 

  53. Bussmann WD, Schupp D. Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary oedema. Am J Cardiol 1978; 41: 931–6

    Article  PubMed  CAS  Google Scholar 

  54. Leier CV, Bambach D, Thompson M, et al. Central and regional hemodynamic effects of intravenous isosorbid dinitrite, nitroglycerin and nitroprusside in patients with congestive heart failure. Am J Cardiol 1981; 48: 1115–23

    Article  PubMed  CAS  Google Scholar 

  55. Packer M. The clinical significance of nitrate tolerance in patients with chronic heart failure. Eur Heart J 1989; 10 Suppl. A: 20–5

    PubMed  Google Scholar 

  56. Kessler PD, Packer M. Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. Am Heart J 1987; 113: 137–43

    Article  PubMed  CAS  Google Scholar 

  57. Yates DR. Pharmacology of flosequinan. Am Heart J 1991; 121: 974–83

    Article  PubMed  CAS  Google Scholar 

  58. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin and angiotensin-converting enzyme inhibitor: results of the flosequinan-ACE inhibitor trial (FACET). Circulation 1993; 88: 492–501

    Article  PubMed  CAS  Google Scholar 

  59. Packer M, Narahara KA, Elkayam U, et al. Double blind, placebocontrolled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol 1993; 22: 65–72

    Article  PubMed  CAS  Google Scholar 

  60. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure Preliminary results of the PROFILE study [abstract]. Circulation 1993; 88: 1–301

    Google Scholar 

  61. Sueta CA, Gheorghiade M, Adams KF, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol 1995; 75: 34A–43A

    Article  PubMed  CAS  Google Scholar 

  62. McKenna WJ, Swedberg K, Zannad F, et al. Experience of chronic intravenous epoprostenol infusion in end-stage cardiac failure: results of FIRST [abstract]. Eur Heart J 1994; 15: 36A

    Google Scholar 

  63. Haywood GA, Adams KF, Gheorghiade M, et al. Is there a role for epoprostenol in the management of heart failure? Am J Cardiol 1995; 75: 44A–50A

    Article  PubMed  CAS  Google Scholar 

  64. Feldman AM. Classification of positive inotropic agents. J Am Coll Cardiol 1993; 22: 1223–7

    Article  PubMed  CAS  Google Scholar 

  65. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1–6

    Article  Google Scholar 

  66. Kubo SH, Gollub S, Bourge R, et al. Beneficial effect of pimobendan on exercise tolerance and quality of life in patients with heart failure. Circulation 1992; 85: 942–9

    Article  PubMed  CAS  Google Scholar 

  67. Feldman AM, Bristow JD, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 329: 149–55

    Article  PubMed  CAS  Google Scholar 

  68. Goldberg LI. Pharmacologic basis for the use of dopamine and related drugs in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1989; 14: S21–8

    Article  PubMed  CAS  Google Scholar 

  69. Leier CV, Heban PT, Huss P, et al. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978; 58: 466–72

    Article  PubMed  CAS  Google Scholar 

  70. Henwood JM, Todd PA. Ibopamine: a preliminary review of itsa pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1988; 36: 11–31

    Article  PubMed  CAS  Google Scholar 

  71. Rajfer SI, Rossen JD, Douglas FL, et al. Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels. Circulation 1986; 73: 740–8

    Article  PubMed  CAS  Google Scholar 

  72. Rousseau MF, Ragioso J, van Eyll C, et al. Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. J Cardiovasc Pharmacol 1992; 19: 155–62

    Article  PubMed  CAS  Google Scholar 

  73. Cas LD, Metra M, Visioli O. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with heart failure. Am J Cardiol 1992; 70: 629–34

    Article  Google Scholar 

  74. Girbes ARJ, Kalisvaart CJ, van Veldhuisen DJ, et al. Effect of ibopamine on renal haemodynamics in patients with severe congestive heart failure. Eur Heart J 1993; 14: 279–93

    Article  PubMed  CAS  Google Scholar 

  75. Cody RJ, Atas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78: 1362–74

    Article  PubMed  CAS  Google Scholar 

  76. Marguiles KB, Barclay PL, Burnett JC. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995; 91: 2036–42

    Article  Google Scholar 

  77. Granger JP Inhibitors of ANF metabolism: potential therapeutic agent in cardiovascular disease. Circulation 1990; 82: 313–5

    Article  PubMed  CAS  Google Scholar 

  78. Motwani JG, Lang CC, Allen MJ, et al. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure. Clin Pharmacol Ther 1993; 54: 661–9

    Article  PubMed  CAS  Google Scholar 

  79. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1987; 41: 233–43

    Article  Google Scholar 

  80. Gaffney TE, Braunwald E. Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 1963; 34: 320–4

    Article  PubMed  CAS  Google Scholar 

  81. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85: 790–804

    Article  PubMed  CAS  Google Scholar 

  82. Bristow MR. Pathophysiology and pharmacologic rationales for clinical management of chronic heart failure with betablocking agents. Am J Cardiol 1993; 71: 12C–22C

    Article  PubMed  CAS  Google Scholar 

  83. Fowler MB. Controlled trials with beta blockers in heart failure: metoprolol as the prototype. Am J Cardiol 1993; 71: 45C–53C

    Article  PubMed  CAS  Google Scholar 

  84. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–6

    Article  PubMed  CAS  Google Scholar 

  85. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25: 1154–61

    Article  PubMed  CAS  Google Scholar 

  86. Fischer ML, Gottleib SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23: 943–50

    Article  Google Scholar 

  87. Swedberg K, Waagstein F, Hjalmarson A, et al. Prolongation of survival in congestive cardiomyopathy by β-receptor blockade. Lancet 1979; 1: 1374–6

    Article  PubMed  CAS  Google Scholar 

  88. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471–5

    Article  PubMed  CAS  Google Scholar 

  89. Chadda K, Goldstein S, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503–10

    Article  PubMed  CAS  Google Scholar 

  90. Gilbert EM, Anderson JL, Deitchman D, et al. Chronic β-blocker-vasodilator therapy improved cardiac function in idiopathic dilated cardiomyopathy: a double blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88; 223–9

    Article  PubMed  CAS  Google Scholar 

  91. Woodley SL, Gilbert EM, Anderson JL, et al. β-blockade with bucindolol in heart failure due to ischemic vs idiopathic dilated cardiomyopathy. Circulation 1991; 84: 2426–41

    Article  PubMed  CAS  Google Scholar 

  92. Ruffolo Jr RR, Gellai M, Hieble JP, et al. The pharmacology of Carvedilol. Eur J Clin Pharmacol 1990; 38 Suppl. 2: S82–8

    Article  PubMed  CAS  Google Scholar 

  93. DasGupta P, Broadhurst P, Raferty EB, et al. Value of Carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 66: 1118–23

    Article  CAS  Google Scholar 

  94. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function in idiopathic dilated cardiomyopathy. Circulation 1991; 84 Suppl. II: H–564

    Google Scholar 

  95. Olsen SL Gilbert EM, Renlund DG, et al. Carvedilol improves symptoms and left ventricular function in patients with congestive heart failure due to ischemic or idiopathic dilated cardiomyopathy [abstract]. J Am Coll Cardiol 1993: 21: 114A

    Google Scholar 

  96. Packer M, Bristow MR, Cohn J, et al. Effect of Carvedilol on the survival of patients with chronic heart failure. Circulation 1995; 92 Suppl.: 1–394

    Article  Google Scholar 

  97. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart falure: a bridge too far. Circulation 1987; 75 Suppl. 5: V56–64

    PubMed  CAS  Google Scholar 

  98. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954–61

    Article  PubMed  CAS  Google Scholar 

  99. Packer M. Pathophysiologic mechanism underlying the adverse effects of calcium-channel blocking drugs in patients with chronic heart failure. Circulation 1989; 80 Suppl. 4: 59–67

    Google Scholar 

  100. Packer M, Nicod P, Khandheiria BR, et al. Randomized, multi-center, double-blind, placebo-controlled evaluation of amlodipine in patients with mild to moderate heart failure [abstract]. J Am Coll Cardiol 1991; 17: 274

    Article  Google Scholar 

  101. Gradman AH. Hemodynamic efects of the vascular selective calcium antagonist felodipine in patients with impaired left ventricular function. Am Heart J 1992; 123: 273–8

    Article  PubMed  CAS  Google Scholar 

  102. Smith WB, DeAbate AC, Gollub SB, et al. Beneficial long-term hemodynamic and clinical effects of amlodipine in chronic heart failure: results of a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study [abstract]. Circulation 1994; 90: I–603

    Google Scholar 

  103. O’Connor CM, Belkin RN, Carson PE, et al. Effect of amlodipine on mode of death in severe chronic heart failure: the PRAISE trial. Circulation 1995; 92 Suppl.: I–143

    Google Scholar 

  104. Cohn J, Ziesche SM, Loss LE, et al. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT III. Circulation 1995; 92 Suppl.: I–143

    Google Scholar 

  105. Chakki CS, Gherghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J 1985; 109: 497–504

    Article  Google Scholar 

  106. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985; 72: 681–5

    Article  PubMed  CAS  Google Scholar 

  107. Bigger Jr JT. Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation 1987; 75: 28–35

    Google Scholar 

  108. Pratt CM, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome from antiarrhythmic therapy: a dangerous imbalance in risk-benefit ratio. Am Heart J 1989; 118: 433–40

    Article  PubMed  CAS  Google Scholar 

  109. Ravid S, Podrid PJ, Lampert S, et al. Congestive heart failure induced by six newer antiarrhythmic drugs. J Am Coll Cardiol 1989; 14: 1326–30

    Article  PubMed  CAS  Google Scholar 

  110. Kaski JC, Girotti LA, Messuti H, et al. Long-term management of sustained recurrent symptomatic ventricular tachycardia with amiodarone. Circulation 1981; 64: 273–9

    Article  PubMed  CAS  Google Scholar 

  111. Cleland JGF, Dargie HJ, Findlay JN, et al. Clinical, haemodynamic and antiarrhythmic effect of long term treatment with amiodarone of patients in heart failure. Br Heart J 1987; 57: 436–45

    Article  PubMed  CAS  Google Scholar 

  112. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016–21

    Article  PubMed  CAS  Google Scholar 

  113. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77–82

    Article  PubMed  CAS  Google Scholar 

  114. Doval CH, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–8

    Article  PubMed  CAS  Google Scholar 

  115. Singh SN, Fletcher RD, Fisher SG, et al., for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77–82

    Article  PubMed  CAS  Google Scholar 

  116. Freedman M, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 1991; 31: 1061–9

    PubMed  CAS  Google Scholar 

  117. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991; 121: 158–71

    Article  PubMed  CAS  Google Scholar 

  118. Baker DW, Wright RF. Management of heart failure: IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA 1994; 272: 1614–8

    Article  PubMed  CAS  Google Scholar 

  119. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. Circulation 1993; 87 Suppl. 6: VI–94–VI–101

    Google Scholar 

  120. McMurray J, Rankin A. Cardiology II: treatment of heart failure and atrial fibrillation and arrhythmias. BMJ 1994; 309: 1631–5

    Article  PubMed  CAS  Google Scholar 

  121. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580–6

    Article  PubMed  CAS  Google Scholar 

  122. Teerlink JR, Löffler BM, Hess P, et al. Role of endothelin in the management of blood pressure in concious rats with chronic hearet failure: acute effects of the endothelin receptor antagonist Ro 47-0203 (Bosentan). Circulation 1994; 90: 2510–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, Central Hospital in Rogaland, N-4011, Stavanger, Norway

    Vernon V. S. Bonarjee & Kenneth Dickstein

Authors
  1. Vernon V. S. Bonarjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Dickstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonarjee, V.V.S., Dickstein, K. Novel Drugs and Current Therapeutic Approaches in the Treatment of Heart Failure. Drugs 51, 347–358 (1996). https://doi.org/10.2165/00003495-199651030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651030-00001

Keywords

Search

Navigation